Citigroup Downgrades Amicus Therapeutics (NASDAQ:FOLD) to Hold

Amicus Therapeutics (NASDAQ:FOLD) was downgraded by investment analysts at Citigroup from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday,Zacks.com reports.

A number of other research firms have also weighed in on FOLD. Cantor Fitzgerald lowered shares of Amicus Therapeutics from an “overweight” rating to a “hold” rating and cut their target price for the stock from $21.00 to $14.50 in a research note on Friday. Wall Street Zen upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Amicus Therapeutics in a report on Monday, December 15th. TD Cowen cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price objective for the company. in a research report on Monday. Finally, Needham & Company LLC lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $15.81.

Amicus Therapeutics Stock Up 0.2%

Shares of NASDAQ FOLD opened at $14.21 on Friday. The stock has a market cap of $4.38 billion, a P/E ratio of -355.16 and a beta of 0.46. The business’s fifty day simple moving average is $9.60 and its 200-day simple moving average is $7.91. Amicus Therapeutics has a 12-month low of $5.51 and a 12-month high of $14.36. The company has a current ratio of 2.99, a quick ratio of 2.09 and a debt-to-equity ratio of 1.70.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.12 by $0.05. The firm had revenue of $169.06 million during the quarter, compared to analysts’ expectations of $165.24 million. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.Amicus Therapeutics’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.10 EPS. As a group, equities analysts predict that Amicus Therapeutics will post 0.15 EPS for the current fiscal year.

Insider Activity at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 77,926 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $10.86, for a total value of $846,276.36. Following the completion of the sale, the chief executive officer directly owned 1,129,782 shares of the company’s stock, valued at approximately $12,269,432.52. The trade was a 6.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ellen Rosenberg sold 36,000 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $10.00, for a total value of $360,000.00. Following the completion of the sale, the insider directly owned 507,710 shares of the company’s stock, valued at approximately $5,077,100. This trade represents a 6.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 319,808 shares of company stock worth $3,293,653. Corporate insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

Hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. increased its holdings in shares of Amicus Therapeutics by 167.6% in the 1st quarter. Russell Investments Group Ltd. now owns 142,569 shares of the biopharmaceutical company’s stock valued at $1,163,000 after acquiring an additional 89,287 shares during the period. Hsbc Holdings PLC grew its holdings in shares of Amicus Therapeutics by 20.4% during the first quarter. Hsbc Holdings PLC now owns 50,456 shares of the biopharmaceutical company’s stock worth $412,000 after buying an additional 8,536 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Amicus Therapeutics in the 1st quarter valued at about $53,000. AlphaQuest LLC raised its stake in Amicus Therapeutics by 248.6% during the 1st quarter. AlphaQuest LLC now owns 37,411 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 26,679 shares during the last quarter. Finally, Jump Financial LLC lifted its position in Amicus Therapeutics by 101.8% during the 1st quarter. Jump Financial LLC now owns 406,168 shares of the biopharmaceutical company’s stock worth $3,314,000 after acquiring an additional 204,941 shares during the period.

Key Headlines Impacting Amicus Therapeutics

Here are the key news stories impacting Amicus Therapeutics this week:

• Positive Sentiment: BioMarin announced a proposed acquisition of Amicus for about $4.8 billion — a take‑over bid typically carries a significant premium and is the primary reason shares are trading up, as it creates a clear path to a buyer and likely takeover consideration for FOLD holders. A $4.8 Billion Reason to Buy BioMarin Stock Today
• Positive Sentiment: Amicus hit a 90+ relative strength (RS) rating, indicating strong price momentum vs. the market — a technical sign that can attract momentum traders and support further gains while the deal story develops. Amicus Therapeutics clears key benchmark, hitting 90-plus RS rating
• Negative Sentiment: Citigroup downgraded FOLD from “strong‑buy” to “hold” (and has cut its price target), signaling reduced conviction from a major firm; that dampens buy‑side enthusiasm and helps explain why upside is constrained despite the acquisition buzz. Citigroup downgrades Amicus Therapeutics (FOLD)
• Negative Sentiment: TD Cowen cut Amicus from “buy” to “hold” and set a $14.50 target — only about ~2% above the current price — which implies limited analyst‑driven upside and may cap the rally until deal specifics or higher bids emerge. Amicus (FOLD) was downgraded to a Hold Rating at TD Cowen
• Negative Sentiment: Multiple outlets report the Citigroup/TD Cowen actions and price‑target cuts (coverage notes aggregated by Zacks/Finviz/Benzinga), reinforcing the narrative that sell‑side sentiment has become more cautious even as deal interest rises. Zacks / Finviz coverage

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.